N/A N=214 Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotics Associated Colitis · Pulmonary Infection
Primary: Presence of AAD — 12 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=98 Probiotics and Antibiotic Associated Diarrhea in Pediatric Complicated Appendicitis
Appendicitis · Appendicitis; Perforation
Primary: Length of Hospital Stay — 121.55; 131.69 hours
Early Phase 1 N=118 Mechanisms of Probiotics and Antibiotic-Associated Diarrhea
Antibiotic-associated Diarrhea
Primary: Change From Baseline Levels of Fecal Short-chain Fatty Acid (With a Particular Focus on Acetate) — 23.55; -13.9; -19.5; 7.25 micromolar
Early Phase 1 N=66 Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics
Antibiotic-associated Diarrhea
Primary: Level of Fecal Short-chain Fatty Acid (SCFA) Acetate — 53.1; 45.2; 42.3; 38.1 micromolar (μM)
Phase 3 N=255 Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection
Antibiotic-Associated Diarrhea · Clostridium Difficile-Associated Diarrhea
Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02
Phase 4 N=33 Impact of Oral Antibiotic Treatment on C. Difficile
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
Phase 3 N=437 Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients
Diarrhea · Clostridium Infections
Primary: The Incidence of Antibiotic-associated Diarrhea. — 216; 221 participants
Phase 3 N=606 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Phase 3 N=608 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT) — 83.4; 82.1 Adjusted percentage of participants
Phase 2 N=34 Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
Phase 3 N=237 A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Clostridium Infections · Diarrhea
Primary: Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal…
Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
Phase 3 N=629 Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
Clostridium Infections · Diarrhea
Primary: Cure Rate at End of Therapy — 85.7; 88.2 Percentage of Participants
Phase 2 N=200 Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
Clostridium Infections
Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants
Phase 3 N=535 PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Clostridium Infections · Diarrhea
Primary: Cure Rate at End of Therapy — 86.7; 87.7 Percentage of Participants
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Phase 4 N=51 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
Clostridium Difficile Infection · Prophylaxis · Vancomycin
Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 3 N=520 Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults.
Antibiotic-associated Diarrhea
Primary: Number of Participants With the Occurrence of Antibiotic-associated Diarrhea (AAD) - Per Protocol (PP) Population — 4; 17 Participants — p=0.007
Phase 2 N=255 Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics
Antibiotic-associated Diarrhea
Primary: Number of Participants Experiencing Diarrhea — 3; 2; 122; 128 Participants
Phase 3 N=632 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 83.8; 85.2 Percentage of participants
Phase 4 N=144 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
Phase 2 N=133 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Enterocolitis Clostridium Difficile Recurrent
Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants
Phase 3 N=609 Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
Clostridium Difficile Infection
Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 81; 85.7 Percentage of participants
N/A N=10 Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)
Diarrhea · Clostridium Difficile
Primary: Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile — 0.18 milligrams/liter
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Phase 3 N=27 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
Phase 4 N=674 Screening to Prophylax Against Clostridium Difficile Infection -
Clostridium Difficile Infection
Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…